No. The FDA has recently approved SciTech’s IND application for ST-001 nanoFenretinide treatment of T-cell NHL. The FDA approved IND provides clearance for ST-001 nanoFenretinide to enter the clinic. The FDA has already granted Orphan Drug Designation for ST-001 nanoFenretinide treatment of T-cell NHL.